Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 2;2015(11):CD006271.
doi: 10.1002/14651858.CD006271.pub3.

Haloperidol for the treatment of nausea and vomiting in palliative care patients

Fay Murray-Brown  1 , Saskie Dorman
Affiliations

Haloperidol for the treatment of nausea and vomiting in palliative care patients

Fay Murray-Brown et al. Cochrane Database Syst Rev. .

Abstract

Background: Nausea and vomiting are common symptoms in patients with terminal, incurable illnesses. Both nausea and vomiting can be distressing. Haloperidol is commonly prescribed to relieve these symptoms. This is an updated version of the original Cochrane review published in Issue 2, 2009, of Haloperidol for the treatment of nausea and vomiting in palliative care patients.

Objectives: To evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients.

Search methods: For this updated review, we performed updated searches of CENTRAL, EMBASE and MEDLINE in November 2013 and in November 2014. We searched controlled trials registers in March 2015 to identify any ongoing or unpublished trials. We imposed no language restrictions. For the original review, we performed database searching in August 2007, including CENTRAL, MEDLINE, EMBASE, CINAHL and AMED, using relevant search terms and synonyms. Handsearching complemented the electronic searches (using reference lists of included studies, relevant chapters and review articles) for the original review.

Selection criteria: We considered randomised controlled trials (RCTs) of haloperidol for the treatment of nausea or vomiting, or both, in any setting, for inclusion. The studies had to be conducted with adults receiving palliative care or suffering from an incurable progressive medical condition. We excluded studies where nausea or vomiting, or both, were thought to be secondary to pregnancy or surgery.

Data collection and analysis: We imported records from each of the electronic databases into a bibliographic package and merged them into a core database where we inspected titles, keywords and abstracts for relevance. If it was not possible to accept or reject an abstract with certainty, we obtained the full text of the article for further evaluation. The two review authors independently assessed studies in accordance with the inclusion criteria. There were no differences in opinion between the authors with regard to the assessment of studies.

Main results: We considered 27 studies from the 2007 search. In this update we considered a further 38 studies from the 2013 search, and two in the 2014 search. We identified one RCT of moderate quality with low risk of bias overall which met the inclusion criteria for this update, comparing ABH (Ativan®, Benadryl®, Haldol®) gel, applied to the wrist, with placebo for the relief of nausea in 22 participants. ABH gel includes haloperidol as well as diphenhydramine and lorazepam. The gel was not significantly better than placebo in this small study; however haloperidol is reported not to be absorbed significantly when applied topically, therefore the trial does not address the issue of whether haloperidol is effective or well-tolerated when administered by other routes (e.g. by mouth, subcutaneously or intravenously). We identified one ongoing trial of haloperidol for the management of nausea and vomiting in patients with cancer, with initial results published in a conference abstract suggesting that haloperidol is effective for 65% of patients. The trial had not been fully published at the time of our review. A further trial has opened, comparing oral haloperidol with oral methotrimeprazine (levomepromazine) for patients with cancer and nausea unrelated to their treatment, which we aim to include in the next review update.

Authors' conclusions: Since the last version of this review, we found one new study for inclusion but the conclusion remains unchanged. There is incomplete evidence from published RCTs to determine the effectiveness of haloperidol for nausea and vomiting in palliative care. Other than the trial of ABH gel vs placebo, we did not identify any fully published RCTs exploring the effectiveness of haloperidol for nausea and vomiting in palliative care patients for this update, but two trials are underway.

PubMed Disclaimer

Conflict of interest statement

FMB has no known conflicts of interest to declare that are relevant to the development of this review.

SD has no known conflicts of interest to declare that are relevant to the development of this review.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Fletcher 2014 {published data only}
    1. Fletcher DS, Coyne PJ, Dodson PW, Parker GG, Wan W, Smith TJ. A randomized trial of the effectiveness of eopical "ABH Gel" (Ativan®, Benadryl®, Haldol®) vs. placebo in cancer patients with nausea. Journal of Pain and Symptom Management 2014;48(5):797-803. [DOI: 10.1016/j.jpainsymman.2014.02.010] - DOI - PubMed

References to studies excluded from this review

Abdelsayed 2007 {published data only}
    1. Abdelsayed G. Management of radiation-induced nausea and vomiting. Experimental Haematology 2007;35(4 Suppl):34-6. - PubMed
Bleicher 2008 {published data only}
    1. Bleicher J, Bhaskara A, Huyck T, Constantino S, Bardia A, Loprinzi CL, et al. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea and vomiting: Results of two pilot trials. Journal of Supportive Oncology 2008;6(1):27-32. - PubMed
Bregni 1991 {published data only}
    1. Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM. Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. European Journal of Cancer 1991;27(5):561-5. - PubMed
Buttner 2004 {published data only}
    1. Buttner M, Walder B, Elm E, Tramer MR. Is low-dose haloperidol a useful antiemetic? A meta-analysis of published and unpublished randomized trials. Anaesthesiology 2004;101:1454-63. - PubMed
Casey 2011 {published data only}
    1. Casey C, Chen LM, Rabow MW. Symptom management in gynaecologic malignancies. Expert Review of Anticancer Therapy 2011;11(7):1077-89. - PubMed
Cerchietti 2000 {published data only}
    1. Cerchietti L, Navigante A, Sauri A, Palazzo F. Hypodermoclysis for control of dehydration in terminal-stage cancer. International Journal of Palliative Nursing 2000;6(8):370-4. - PubMed
Cheung 2011 {published data only}
    1. Cheung W, Zimmerman C. Pharmacologic management of cancer-related pain, dyspnoea and nausea. Seminars in Oncology 2011;38(3):450-9. - PubMed
Chiu 2007 {published data only}
    1. Chiu W. Update on antiemetics of chemotherapy. Journal of Internal Medicine of Taiwan 2007;18(6):342-9.
Chow 2010 {published data only}
    1. Chow C, Leung AK, Hon KL. Acute gastroenteritis: from guidelines to real life. Clinical and Experimental Gastroenterology 2010;3(1):97-112. - PMC - PubMed
Christman 1974 {published data only}
    1. Christman RS, Weinstein RA, Larose JB. Low-dose haloperidol as antiemetic treatment in gastrointestinal disorders: a double-blind study. Current Therapeutic Research 1974;16(11):1171-5. - PubMed
Christo 2003 {published data only}
    1. Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiology Clinics of North America 2003;21:699-713. - PubMed
Clary 2009 {published data only}
    1. Clary P, Lawson P. Pharmacologic pearls for end of life care. American Family Physician 2009;79(12):1059-65. - PubMed
Cole 1974 {published data only}
    1. Cole DR, Duffy DF. Haloperidol for radiation sickness: control of associated nausea, vomiting, and anorexia. New York State Journal of Medicine 1974;74(9):1558-662. - PubMed
Cole 1994 {published data only}
    1. Cole RM, Robinson F, Harvey L, Trethowan K, Murdoch B. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. Journal of Pain and Symptom Management 1994;9:48-50. - PubMed
Davis 2010 {published data only}
    1. Davis M, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy of radiation. Journal of Pain and Symptom Management 2010;39(4):756-67. - PubMed
De Vries 1969 {published data only}
    1. De Vries PM. A double-blind cross-over clinical valuation of metoclopramide and a combination of haloperidol and isopropamide iodide in gastroenterology. Arzneimittel-Forschung 1969;19:1766-7. - PubMed
DiVall 2007 {published data only}
    1. DiVall M, Cervosimo R. Prevention and treatment of chemotherapy-induced nausea and vomiting. Formulary 2007;42(6):378-88.
Ettinger 2007 {published data only}
    1. Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al. Antiemesis: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 2007;5:12-33. - PubMed
Ettinger 2009 {published data only}
    1. Ettinger D, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, et al. Antiemesis. Journal of the National Comprehensive Cancer Network 2009;7(5):572-95. - PubMed
Feyer 2011 {published data only}
    1. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Annals of Oncology 2011;22(1):30-8. - PubMed
Findlay 1993 {published data only}
    1. Findlay M, Simes RJ, Cox K, Carmichael K, Chey T, McNeil E, et al. A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimen. European Journal of Cancer 1993;29A(3):309-15. - PubMed
Fischberg 2007 {published data only}
    1. Fischberg D. Randomised controlled trial of three antiemetics in the emergency department. Journal of Pain and Palliative Care Pharmacotherapy 2007;21(1):73-4.
Getto 2011 {published data only}
    1. Getto L, Zeserson E, Breyer M. Vomiting, diarrhoea, constipation and gastroenteritis. Emergency Medicine Clinics of North America 2011;29(2):211-37. - PMC - PubMed
Glare 2004 {published data only}
    1. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Supportive Care Cancer 2004;12:432-40. - PubMed
Glare 2011 {published data only}
    1. Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clinical Interventions in Ageing 2011;6(1):243-59. - PMC - PubMed
Gonzales 2011 {published data only}
    1. Gonzales M, Widera E. Nausea and other nonpain symptoms in long-term care. Clinics in Geriatric Medicine 2011;27(2):213-28. - PubMed
Grunberg 1984 {published data only}
    1. Grunberg SM, Gala KV, Lampenfeld M, Jamin D, Johnson K, Cariffe P, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. Journal of Clinical Oncology 1984;2(7):782-7. - PubMed
Grunberg 2010 {published data only}
    1. Grunberg S, Clark-Snow RA, Koeller J. Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Supportive Care in Cancer 2010;18 Suppl 1:S1-10. - PubMed
Hardy 2010 {published data only}
    1. Hardy J, O'Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. Journal of Pain and Symptom Management 2010;40(1):111-6. - PubMed
Herndon 2002 {published data only}
    1. Herndon CM, Jackson IK, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 2002;22:240-50. - PubMed
Herrstedt 2008 {published data only}
    1. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nature Clinical Practice Oncology 2008;5(1):32-43. - PubMed
Jordan 2007 {published data only}
    1. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of anti-emetic drugs. Critical Reviews in Oncology/Hematology 2007;61(2):162-75. - PubMed
Kohara 2005 {published data only}
    1. Kohara H, Ueoka H, Takeyama H, Murakami T, Morita T. Sedation for terminally ill patients with cancer with uncontrollable physical distress. Journal of Palliative Medicine 2005;8(1):20-5. - PubMed
Ladabaum 1999 {published data only}
    1. Ladabaum U, Hasler WL. Novel approaches to the treatment of nausea and vomiting. Digestive Diseases 1999;17:125-32. - PubMed
Liem‐Moolenar 2010 {published data only}
    1. Liem-Moolenaar M, te Beek ET, Kam ML, Franson KL, Kahn RS, Hijman R, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. Journal of Psychopharmacology 2010;24(11):1697-708. - PubMed
Lohr 2008 {published data only}
    1. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer Journal 2008;14(2):85-93. - PubMed
McHugh 2011 {published data only}
    1. McHugh M, Miller-Saultz D. Assessment of gastrointestinal symptoms in advanced illness. Primary Care - Clinics in Office Practice 2011;38(2):225-46. - PubMed
McNicol 2003 {published data only}
    1. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. Journal of Pain 2003;4(5):231-56. - PubMed
Mercadante 2007 {published data only}
    1. Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. Journal of Pain and Symptom Management 2007;33(2):217-23. - PubMed
Naeim 2008 {published data only}
    1. Naeim A. Evidence-based recommendations for cancer nausea and vomiting. Journal of Clinical Oncology 2008;26(23):3903-10. - PubMed
Navari 2007 {published data only}
    1. Navari M. Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Community Oncology 2007;4 Suppl 1:3-11.
Neidhart 1981 {published data only}
    1. Neidhart JA, Gagen M, Young DM, Wilson HE. Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide. Cancer 1981;47:1439-43. - PubMed
O'Connor 2011 {published data only}
    1. O'Connor B, Creedon B. Pharmacological treatment of bowel obstruction in cancer patients. Expert Opinion on Pharmacotherapy 2011;12(14):2205-14. - PubMed
Owens 1984 {published data only}
    1. Owens NJ, Schauer AR, Nightingale CH, Golub GR, Martin RS, Williams HM, et al. Antiemetic efficacy of prochlorperazine, haloperidol, and droperidol in cisplatin-induced emesis. Clinical Pharmacy 1984;3:167-70. - PubMed
Perkins 2009 {published data only}
    1. Perkins P, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No: CD006271. [DOI: 10.1002/14651858.CD006271.pub2] - DOI - PubMed
Pleuvry 2009 {published data only}
    1. Pleuvry B. Physiology and pharmacology of nausea and vomiting. Anaesthesia and Intensive Care Medicine 2009;10(12):597-601.
Porreca 2009 {published data only}
    1. Porreca F, Ossipov M. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: Mechanisms, implications and management options. Pain Medicine 2009;10(4):654-62. - PubMed
Ripamonti 2001 {published data only}
    1. Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Supportive Care in Cancer 2001;9:223-33. - PubMed
Robbins 1975 {published data only}
    1. Robbins EL, Nagel JD. Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. Journal of the American Geriatrics Society 1975;23:38-41. - PubMed
Roeland 2010 {published data only}
    1. Roeland E, Mitchell W, Elia G, Thornberry K, Herman H, Cain J, et al. Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 1: Physical symptoms. Journal of Supportive Oncology 2010;8(3):100-16. - PubMed
Saller 1985 {published data only}
    1. Saller R, Hellenbrecht D. The benefit and risk of high dose metoclopramide in comparison to high dose haloperidol or trifluorpromazine in cisplatin-induced emesis. Klinische Wochenschrift 1985;63:428-32. - PubMed
Siden 2008 {published data only}
    1. Siden H. Haloperidol as a palliative anti-emetic in a toddler: an evidence-base challenge. Journal of Pain and Symptom Management 2008;35(3):235-8. - PubMed
Silvey 1988 {published data only}
    1. Silvey L, Carpenter JT, Wheeler RH, Lee J, Conolley C. A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. Journal of Clinical Oncology 1988;6(9):1397-400. - PubMed
Smith 2011 {published data only}
    1. Smith T, Ritter JK, Coyne PJ, Parker GL, Dodson P, Fletcher DS. Testing the cutaneous absorption of lorazepam, diphenhydramine and haloperidol gel (ABH gel) used for cancer-related nausea. Journal of Clinical Oncology 2011;29:Abstract 9021.
Smith 2012a {published data only}
    1. Smith T, Fletcher D, Coyne P, Dodson P, Parker G. ABH gel is not absorbed from the skin of normal volunteer so cannot be effective against nausea. In: Journal of Pain and Symptom Management. Conference: Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association. Denver, US, 2012.
Sperry 2007 {published data only}
    1. Sperry M. A review of the 2006 ASCO antiemetic guidelines update. US Pharmacist 2007;32(1):22-8.
Stapleton 2009 {published data only}
    1. Stapleton J, Wo J. Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics. Gastrointestinal Endoscopy Clinics of North America 2009;19(1):57-72. - PubMed
Tatum 2009 {published data only}
    1. Tatum P. Haloperidol for nausea and vomiting. Journal of Pain and Palliative Care Pharmacotherapy 2009;23(4):426-7.
Tornetta 1971 {published data only}
    1. Tornetta FJ. Haloperidol as an antiemetic - guest discussion. Anesthesia and Analgesia - Current Researches 1971;50(6):1024-6. - PubMed
Tornetta 1972 {published data only}
    1. Tornetta FJ. Double-blind evaluation of haloperidol for antiemetic activity. Anesthesia and analgesia. Current Researches 1972;51(6):964-7. - PubMed
Trigg 2008 {published data only}
    1. Trigg M, Inverso D. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplantation 2008;42(8):501-6. - PubMed
Trigg 2010 {published data only}
    1. Trigg M. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice. Journal of Oncology Pharmacy Practice 2010;16(4):233-44. - PubMed
Weschules 2005 {published data only}
    1. Weschules DJ. Tolerability of the compound ABHR in hospice patients. Journal of Palliative Medicine 2005;8(6):1135-43. - PubMed
White 2006 {published data only}
    1. White C, McPherson A, McCann MA, Sadler A, Fyvie J. Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic. Palliative Medicine 2006;20:215-6. - PubMed

References to ongoing studies

ACTRN12610000481077 {published data only}
    1. Hardy J, Yates P, Philip J, Martin P, Glare P, Currow D. A targeted versus empiric approach to antiemetic use in advanced cancer. In: In: MASCC/ISOO International Symposium on Supportive Care in Cancer. 26 June 2014. [http:/mascc2014.meetingxpert.net/MASCC_595/poster_96766/program.aspx/anc...
    1. Yates P. The effectiveness of guideline driven antiemetic therapy versus single agent antiemetic therapy in patients with cancer and nausea not related to cancer therapy. Australian New Zealand Clinical Trials Registry 2010. [ACTRN12610000481077] [https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=1261...]
ACTRN12615000177550 {published data only}
    1. Hardy JR. A randomised, controlled, double blind study of oral methotrimeprazine versus oral haloperidol in patients with cancer and nausea not related to anticancer therapy (Nausea study 3), to compare the effectiveness of oral methotrimeprazine versus oral haloperidol in improving the management of nausea in patients with cancer and nausea not related to anticancer therapy. World Health Organization International Clinical Trials Registry Platform 23 February 2015. [ACTRN12615000177550] [http://www.anzctr.org.au/ACTRN1261500077550.aspx]

Additional references

Barton 1975
    1. Barton MD, Libonati M, Cohen PJ. The use of haloperidol for treatment of postoperative nausea and vomiting--a double-blind placebo-controlled trial. Anesthesiology 1975;42(4):508-12. - PubMed
Bentley 2001
    1. Bentley A, Boyd K. Use of clinical pictures in the management of nausea and vomiting. Palliative Medicine 2001;15:247-53. - PubMed
Critchley 2001
    1. Critchley P, Plach N, Grantham M, Marshall D, Taniguchi A, Latimer E, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. Journal of Pain and Symptom Management 2001;22:631-4. - PubMed
Edmonds 2001
    1. Edmonds P, Karlsen S, Khan S, Addington-Hall J. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliative Medicine 2001;15:287-95. - PubMed
Egerton‐Warburton 2014
    1. Egerton-Warburton D, Meek R, Mee MJ, Braitberg G. Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. Annals of Emergency Medicine 2014;64(5):526-32. - PubMed
Ewing 2004
    1. Ewing G, Rogers M, Barclays S, McCabe J, Martin A, Todd C. Recruiting patients into a primary care based study of palliative care: why is it so difficult? Palliative Medicine 2004;18:452-9. - PubMed
Hardy 1997
    1. Hardy JR. Placebo-controlled trials in palliative care: the argument for. Palliative Medicine 1997;11(5):415-8. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Hirst 2001
    1. Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No: CD003346. [DOI: 10.1002/14651858.CD003346] - DOI - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996;17:1-12. - PubMed
Jordhoy 1999
    1. Jordhoy M, Kaasa S, Fayers P, Ovreness T, Underland G, Ahlner-Elmqvist M. Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliative Medicine 1999;13:299-310. - PubMed
Keeley 2007
    1. Keeley P. Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clinical Evidence 2007;06:2406. - PMC - PubMed
Kirkham 1997
    1. Kirkham SR, Abel J. Placebo-controlled trials in palliative care: the argument against. Palliative Medicine 1997;11(6):489-92. - PubMed
Klinkenberg 2004
    1. Klinkenberg M, Willems DL, Wal G, Deeg DJH. Symptom burden in the last week of life. Journal of Pain and Symptom Management 2004;27:5-13. - PubMed
Kris 1996
    1. Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 1996;78(10):2193-8. - PubMed
Lindqvist 2013
    1. Lindqvist O, Lundquist G, Dickman A, Bükki J, Lunder U, Hagelin CL, et al. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion. Journal of Palliative Medicine 2013;16(1):38-43. - PubMed
L’Abbé 1987
    1. L’Abbé KA, Detsky AS, O’Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-32. - PubMed
Mannix 2004
    1. Mannix KA. Palliation of nausea and vomiting. In: Oxford Textbook of Palliative Medicine. Oxford University Press, 2004.
McLean 2013
    1. McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. Journal of Pain and Palliative Care Pharmacotherapy 2013;27(2):132-5. - PubMed
Miller 2008
    1. Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration. Pharmacotherapy 2008;28(7):875-82. - PubMed
Pereira 2012
    1. Pereira J. Study comparing olanzapine with haloperidol for the relief of nausea and vomiting in patients with advanced cancer. clinicaltrials.gov. [ISRCTN58624349] [NCT00124930] [https://clinicaltrials.gov/ct2/show/NCT00124930?term=Haloperidol&rank=59]
Prommer 2012
    1. Prommer E. Role of haloperidol in palliative medicine: an update. American Journal of Hospice and Palliative Medicine 2012;29(4):295-301. - PubMed
Reuben 1986
    1. Reuben DB, Mor V. Nausea and vomiting in terminal cancer patients. Archives of Internal Medicine 1986;146:2021-3. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sanderson 2013
    1. Sanderson C, Hardy J, Spruyt O, Currow DC. Placebo and nocebo effects in randomized controlled trials: the implications for research and practice. Journal of Pain and Symptom Management 2013;46(5):722-30. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Smith 2012b
    1. Smith HR, Cox LR, Smith BR. Dopamine receptor antagonists. Annals of Palliative Medicine 2012;1(2):137-42. - PubMed
Solano 2006
    1. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. Journal of Pain and Symptom Management 2006;31(1):58-69. - PubMed
Susman 2001
    1. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatric Quarterly 2001;72:325-36. - PubMed
To 2014
    1. To TH, Agar M, Yates P, Currow DC. Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors. Journal of Palliative Medicine 2014;17(9):1032-6. - PubMed
Twycross 1998
    1. Twycross R, Back I. Nausea and vomiting in advanced cancer. European Journal of Palliative Care 1998;5:39-45.
Twycross 2014
    1. Twycross R, Wilcock A, Howard P. Palliative Care Formulary. 5th edition. palliativedrugs.com, 2014.

Publication types